SALT LAKE CITY, Nov. 13, 2019 /PRNewswire/ -- Lipocine Inc.
(NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused
on metabolic and endocrine disorders, today announced the launch of
a public offering of units consisting of shares of its common stock
(or pre-funded warrants) and warrants to purchase its common stock.
The shares of common stock (or pre-funded warrants) and warrants
comprising the units are immediately separable and will be issued
separately, but will be purchased together. The offering is being
conducted on a best-efforts basis and is subject to market and
other conditions, and there can be no assurance as to whether or
when the offering may be completed or as to the actual size or
terms of the offering.
Roth Capital Partners is acting as sole agent for the public
offering.
The offering is being made pursuant to a shelf registration
statement on Form S-3 (File No. 333-220942) (including a
prospectus) previously filed with and declared effective by the
U.S. Securities and Exchange Commission (the "SEC"). A prospectus
supplement describing the terms of the offering will be filed with
the SEC.
A copy of the preliminary prospectus supplement and the
accompanying prospectus relating to these securities may be
obtained, when available, by contacting Roth Capital Partners, 888
San Clemente Drive, Suite 400, Newport
Beach, CA 92660, (800) 678-9147. Electronic copies of the
preliminary prospectus supplement and the accompanying prospectus
will also be available free of charge on the website of the SEC at
www.sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy securities, nor will there be any
sale of the securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such
jurisdiction.
About Lipocine
Lipocine Inc. is a clinical-stage biopharmaceutical company
focused on metabolic and endocrine disorders using its
proprietary drug delivery technologies. Lipocine's clinical
development pipeline includes TLANDO, LPCN 1144, TLANDO XR ("LPCN
1111"), LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of
testosterone containing testosterone undecanoate, is designed to
help restore normal testosterone levels in hypogonadal men.
Lipocine received a complete response letter from the FDA related
to TLANDO on November 8, 2019. LPCN
1144, an oral product of bioidentical testosterone, recently
completed a proof-of-concept clinical study demonstrating the
potential utility in the treatment of pre-cirrhotic NASH.
TLANDO XR, a novel oral prodrug of testosterone, originated
and is being developed by Lipocine as a next-generation oral
testosterone product with potential for once-daily dosing. In a
phase 2 clinical evaluation when administered as once daily or
twice daily TLANDO XR met the typical primary and secondary end
points. LPCN 1148 is an oral prodrug of bioidentical testosterone
targeted for the treatment of NASH cirrhosis. LPCN 1107 is
potentially the first oral hydroxyprogesterone caproate product
candidate, with end of phase 2 meeting completed, indicated for the
prevention of recurrent preterm birth and has been granted orphan
drug designation by the FDA. For more information, please
visit www.lipocine.com.
Forward-Looking Statements
This release contains "forward-looking statements" that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and include statements that are not
historical facts, including statements regarding Lipocine's
intention to conduct a public offering of its securities and other
statements that are not historical facts. Investors are cautioned
that all such forward-looking statements involve risks and
uncertainties, including, without limitation, the risks that the
public offering of common stock and warrants may not close, the
funds raised, if any, may not meet our needs and the terms may not
be advantageous to us, risks that the FDA will not approve any of
our products, risks related to our products, expected product
benefits not being realized, clinical and regulatory expectations
and plans not being realized, new regulatory developments and
requirements, risks related to the FDA approval process including
the receipt of regulatory approvals, the results and timing of
clinical trials, patient acceptance of Lipocine's products, the
manufacturing and commercialization of Lipocine's products, and
other risks detailed in Lipocine's filings with the SEC, including,
without limitation, its Form 10-K and other reports on Forms 8-K
and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Lipocine assumes no obligation to update or revise
publicly any forward-looking statements contained in this release,
except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lipocine-announces-launch-of-public-offering-of-common-stock-and-warrants-300957661.html
SOURCE Lipocine Inc.